Skip to content

US · TXG · MEDICAL - HEALTHCARE INFORMATION SERVICES

10x Genomics, Inc. (TXG) intrinsic value and stock valuation

$51.80as of 2026-11-21 · Mkt cap 6.03B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

10x Genomics, Inc. DCF and intrinsic value

InvestorsCraft values TXG with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TXG’s statements →

10x Genomics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Pleasanton, CA 94588-3260 10xgenomics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$642.8M+16.6% 5y CAGRd
20172025
Net income
-$-43.54M
20172025
Free cash flow
$130.1M
20172025
Total equity
$796.3M+1.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$642.8M$610.8M$618.7M$516.4M$490.5M
Operating income-$-110.89M-$-194.56M-$-265.33M-$-167.94M-$-52.91M
Net income-$-43.54M-$-182.63M-$-255.1M-$-166M-$-58.22M
EPSd-$-349.02K-$-1.52M-$-2.18M-$-1.46M-$-527.59K
Operating cash flow$136.1M$6.66M-$-15.2M-$-33.61M-$-21.37M
Capital expenditure-$-5.93M-$-12.39M-$-49.52M-$-131.66M-$-101.28M
Free cash flow$130.1M-$-5.73M-$-64.72M-$-165.27M-$-122.65M
Total assets$1.04B$918.6M$965.1M$1.03B$1.02B
Total debt$157.7M$82.6M$95.4M$95.2M$82M
Net debt-$-316.23M-$-261.45M-$-263.91M-$-124.57M-$-505.47M
Total equity$796.3M$710.1M$741M$805.7M$817.6M
Cash and short-term investments$523.4M$393.4M$388.7M$430M$587.5M
Income statement
20252024202320222021
Revenue$642.8M$610.8M$618.7M$516.4M$490.5M
Cost of revenue$198.9M$196.3M$209.4M$120.4M$74.1M
Gross profit$443.9M$414.5M$409.3M$396M$416.4M
Research and development expenses$238.6M$264.7M$270.3M$265.7M$211.8M
Selling, general and administrative expenses$316.1M$344.3M$343.3M$298.3M$257.6M
Other expenses$0.00$0.00$61M$0.00$0.00
Operating expenses$554.8M$609M$674.6M$564M$469.3M
Cost and expenses$753.7M$805.3M$884.1M$684.4M$543.4M
Interest income$20.1M$18.5M$16.9M$6.65M$210K
Interest expense$0.00$0.00$30K$480K$870K
Depreciation and amortization$43.8M$43.7M$43.6M$33M$28.3M
Ebitda$3.91M-$-133.99M-$-205.11M-$-128.49M-$-24.59M
Operating income-$-110.89M-$-194.56M-$-265.33M-$-167.94M-$-52.91M
Total other income/expenses, net$71M$16.9M$16.6M$5.97M-$-800K
Income before tax-$-39.91M-$-177.7M-$-248.76M-$-161.97M-$-53.72M
Income tax expense$3.64M$4.93M$6.34M$4.03M$4.51M
Net income-$-43.54M-$-182.63M-$-255.1M-$-166M-$-58.22M
Weighted average shares outstanding$124.8M$120.5M$117.2M$113.9M$110.4M
Weighted average diluted shares outstanding$124.8M$120.5M$117.2M$113.9M$110.4M
Balance sheet
20252024202320222021
Cash and short-term investments$523.4M$393.4M$388.7M$430M$587.5M
Net receivables$82.5M$87.9M$114.8M$104.2M$85.3M
Inventory$56.3M$83.1M$73.7M$81.6M$60M
Total current assets$684.5M$584.4M$596M$635M$747.6M
Property, plant and equipment, net$287.2M$309.9M$344.9M$359.2M$230.4M
Goodwill and intangible assets$66.8M$20.2M$21.1M$27.4M$29.9M
Long-term investments$0.00$0.00$0.00$0.00$7.6M
Total non-current assets$356.9M$334.3M$369.1M$393.9M$271.2M
Total assets$1.04B$918.6M$965.1M$1.03B$1.02B
Accounts payable$12.7M$12.9M$15.7M$21.6M$17.4M
Short-term debt$11M$9.29M$11.5M$9.04M$5.13M
Deferred revenue$23.9M$20.7M$13.2M$7.87M$5.34M
Total current liabilities$153.5M$117.6M$127.2M$131M$110.4M
Long-term debt$146.8M$73.3M$83.9M$86.1M$76.9M
Deferred revenue, non-current$10.5M$12.5M$8.81M$3.17M$0.00
Total non-current liabilities$91.6M$90.9M$96.9M$92.3M$90.9M
Capital lease obligations$73.4M$82.6M$95.4M$95.2M$82M
Total liabilities$245M$208.5M$224.1M$223.2M$201.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-1.51B-$-1.47B-$-1.28B-$-1.03B-$-863.32M
Accumulated other comprehensive income (loss)$230K-$-490K-$-430K-$-4.33M$20K
Total equity$796.3M$710.1M$741M$805.7M$817.6M
Total investments$49.4M$49.3M$29.4M$210.2M$7.6M
Total debt$157.7M$82.6M$95.4M$95.2M$82M
Net debt-$-316.23M-$-261.45M-$-263.91M-$-124.57M-$-505.47M
Cash flow statement
20252024202320222021
Net income-$-43.54M-$-182.63M-$-255.1M-$-166M-$-58.22M
Depreciation and amortization$43.8M$43.7M$43.6M$33M$28.3M
Stock-based compensation$109.1M$140.8M$167M$136.9M$96M
Change in working capital$24.9M$1.25M$17.3M-$-39.42M-$-87.44M
Accounts receivable$6.44M$27M-$-10.61M-$-18.95M-$-34.04M
Inventory$28M-$-9.78M$7.87M-$-21.19M-$-30.13M
Accounts payable-$-2.13M-$-3.35M-$-6.02M$5.86M$11.1M
Net cash provided by operating activities$136.1M$6.66M-$-15.2M-$-33.61M-$-21.37M
Investments in property, plant and equipment-$-5.93M-$-12.39M-$-48.6M-$-131.66M-$-101.28M
Acquisitions, net-$-9.27M$0.00$0.00-$-4M-$-5.45M
Net cash used for investing activities-$-13.44M-$-32.63M$133.5M-$-350.89M-$-106.73M
Common stock issued$6.8M$10.9M$19.5M$21.2M$40.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.8M$10.9M$13.7M$15.8M$35.3M
Net change in cash$129.9M-$-15.22M$131.9M-$-368.72M-$-92.57M
Cash at end of period$474M$344.1M$359.3M$227.4M$596.1M
Operating cash flow$136.1M$6.66M-$-15.2M-$-33.61M-$-21.37M
Capital expenditure-$-5.93M-$-12.39M-$-49.52M-$-131.66M-$-101.28M
Free cash flow$130.1M-$-5.73M-$-64.72M-$-165.27M-$-122.65M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 10x Genomics, Inc.

        Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

        CEO
        Serge Saxonov
        Employees
        1.18K
        Beta
        2.04

        Explore

        Frequently asked questions

        What is the intrinsic value of 10x Genomics, Inc. (TXG)?

        10x Genomics, Inc. (TXG) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TXG undervalued?

        TXG trades at a price of $51.80 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.